UK markets open in 6 hours 23 minutes

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
0.9915-0.0080 (-0.80%)
At close: 08:44AM BST
Full screen
Previous close0.9995
Open0.0000
Bid0.9670 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume4
Avg. volume2,113
Market cap112.462M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings date29 Jul 2024 - 02 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

    Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sachs G

  • Globe Newswire

    Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

    Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights05/31/2024 96,493,078 Total gross of voting rights: 96,493,078 Total net* of voting rights: 96,236,383 * Net total = total number of voting rights attached to shares – shares without voting

  • Globe Newswire

    DBV Technologies Announces Plan to Implement ADS Ratio Change

    Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value